Loading…

A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients

Intravenous beta-lactam antibiotics are the most prescribed antibiotic class in US hospitalized patients of all ages; therefore, optimizing their dosing is crucial. Bactericidal killing is best predicted by the time in which beta-lactam drug concentrations are maintained above the organism's mi...

Full description

Saved in:
Bibliographic Details
Published in:The journal of pediatric pharmacology and therapeutics 2022-01, Vol.27 (3), p.214-227
Main Authors: Imburgia, Taylor A, Kussin, Michelle L
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2474-23b9e4fe8b18ad089569db0c5e5af0e91277a1af372cbc754869be97402a58213
cites cdi_FETCH-LOGICAL-c2474-23b9e4fe8b18ad089569db0c5e5af0e91277a1af372cbc754869be97402a58213
container_end_page 227
container_issue 3
container_start_page 214
container_title The journal of pediatric pharmacology and therapeutics
container_volume 27
creator Imburgia, Taylor A
Kussin, Michelle L
description Intravenous beta-lactam antibiotics are the most prescribed antibiotic class in US hospitalized patients of all ages; therefore, optimizing their dosing is crucial. Bactericidal killing is best predicted by the time in which beta-lactam drug concentrations are maintained above the organism's minimum inhibitory concentration (MIC), rather than achievement of a high peak concentration. As such, administration of beta-lactam antibiotics via extended or continuous infusions over a minimum of 3 hours, rather than standard infusions over approximately 30 minutes, has been associated with improved achievement of pharmacodynamic targets and improved clinical outcomes in adult medical literature. This review summarizes the pediatric medical literature. Applicable studies include pharmacodynamic models, case series, retrospective analyses, and prospective studies on the use of extended infusion and continuous infusion penicillins, cephalosporins, carbapenems, and monobactams in neonates, infants, children, and adolescents. Specialized patient populations with unique pharmacokinetics and high-risk infections (neonates, critically ill, febrile neutropenia, cystic fibrosis) are also reviewed. While more studies are needed to confirm prospective clinical outcomes, the current body of evidence suggests extended and continuous infusions of beta-lactam antibiotics are well tolerated in children and improve achievement of pharmacokineticpharmacodynamic targets with similar or superior clinical outcomes, particularly in infections associated with high MICs.
doi_str_mv 10.5863/1551-6776-27.3.214
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8939270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2645470260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2474-23b9e4fe8b18ad089569db0c5e5af0e91277a1af372cbc754869be97402a58213</originalsourceid><addsrcrecordid>eNpVUUtLAzEQDqLYUvsHPEiOXrbmudlcBC1VC4UWUfAWstlZjbTZutmt-u_d0lp0LnOY7zHzDULnlIxklvIrKiVNUqXShKkRHzEqjlCfcU4TLrKXY9Q_AHpoGOM76UoIRaQ4RT0uuSRU6j6a3-BH2Hj4xFWJJ18NhAIKbEOBx1VofGirNuJpKNvoq4BvobHJzLrGriL2AS-g8LapvcML23gITTxDJ6VdRhju-wA9302exg_JbH4_Hd_MEseEEgnjuQZRQpbTzBYk0zLVRU6cBGlLApoypSy1JVfM5U5JkaU6B60EYVZmjPIBut7prtt8BYXrvGu7NOvar2z9bSrrzf9J8G_mtdqYTHPNFOkELvcCdfXRQmzMykcHy6UN0N1sWCpkFxdLt1C2g7q6irGG8mBDidk-w2yzNtusDVOGm-4ZHeni74IHym_0_AfKFoTu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2645470260</pqid></control><display><type>article</type><title>A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients</title><source>PubMed Central</source><creator>Imburgia, Taylor A ; Kussin, Michelle L</creator><creatorcontrib>Imburgia, Taylor A ; Kussin, Michelle L</creatorcontrib><description>Intravenous beta-lactam antibiotics are the most prescribed antibiotic class in US hospitalized patients of all ages; therefore, optimizing their dosing is crucial. Bactericidal killing is best predicted by the time in which beta-lactam drug concentrations are maintained above the organism's minimum inhibitory concentration (MIC), rather than achievement of a high peak concentration. As such, administration of beta-lactam antibiotics via extended or continuous infusions over a minimum of 3 hours, rather than standard infusions over approximately 30 minutes, has been associated with improved achievement of pharmacodynamic targets and improved clinical outcomes in adult medical literature. This review summarizes the pediatric medical literature. Applicable studies include pharmacodynamic models, case series, retrospective analyses, and prospective studies on the use of extended infusion and continuous infusion penicillins, cephalosporins, carbapenems, and monobactams in neonates, infants, children, and adolescents. Specialized patient populations with unique pharmacokinetics and high-risk infections (neonates, critically ill, febrile neutropenia, cystic fibrosis) are also reviewed. While more studies are needed to confirm prospective clinical outcomes, the current body of evidence suggests extended and continuous infusions of beta-lactam antibiotics are well tolerated in children and improve achievement of pharmacokineticpharmacodynamic targets with similar or superior clinical outcomes, particularly in infections associated with high MICs.</description><identifier>ISSN: 1551-6776</identifier><identifier>EISSN: 2331-348X</identifier><identifier>DOI: 10.5863/1551-6776-27.3.214</identifier><identifier>PMID: 35350159</identifier><language>eng</language><publisher>United States: Pediatric Pharmacy Advocacy Group</publisher><subject>Education</subject><ispartof>The journal of pediatric pharmacology and therapeutics, 2022-01, Vol.27 (3), p.214-227</ispartof><rights>Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2022.</rights><rights>Pediatric Pharmacy Association. All rights reserved. For permissions, email: 2022 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2474-23b9e4fe8b18ad089569db0c5e5af0e91277a1af372cbc754869be97402a58213</citedby><cites>FETCH-LOGICAL-c2474-23b9e4fe8b18ad089569db0c5e5af0e91277a1af372cbc754869be97402a58213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939270/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939270/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35350159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Imburgia, Taylor A</creatorcontrib><creatorcontrib>Kussin, Michelle L</creatorcontrib><title>A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients</title><title>The journal of pediatric pharmacology and therapeutics</title><addtitle>J Pediatr Pharmacol Ther</addtitle><description>Intravenous beta-lactam antibiotics are the most prescribed antibiotic class in US hospitalized patients of all ages; therefore, optimizing their dosing is crucial. Bactericidal killing is best predicted by the time in which beta-lactam drug concentrations are maintained above the organism's minimum inhibitory concentration (MIC), rather than achievement of a high peak concentration. As such, administration of beta-lactam antibiotics via extended or continuous infusions over a minimum of 3 hours, rather than standard infusions over approximately 30 minutes, has been associated with improved achievement of pharmacodynamic targets and improved clinical outcomes in adult medical literature. This review summarizes the pediatric medical literature. Applicable studies include pharmacodynamic models, case series, retrospective analyses, and prospective studies on the use of extended infusion and continuous infusion penicillins, cephalosporins, carbapenems, and monobactams in neonates, infants, children, and adolescents. Specialized patient populations with unique pharmacokinetics and high-risk infections (neonates, critically ill, febrile neutropenia, cystic fibrosis) are also reviewed. While more studies are needed to confirm prospective clinical outcomes, the current body of evidence suggests extended and continuous infusions of beta-lactam antibiotics are well tolerated in children and improve achievement of pharmacokineticpharmacodynamic targets with similar or superior clinical outcomes, particularly in infections associated with high MICs.</description><subject>Education</subject><issn>1551-6776</issn><issn>2331-348X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVUUtLAzEQDqLYUvsHPEiOXrbmudlcBC1VC4UWUfAWstlZjbTZutmt-u_d0lp0LnOY7zHzDULnlIxklvIrKiVNUqXShKkRHzEqjlCfcU4TLrKXY9Q_AHpoGOM76UoIRaQ4RT0uuSRU6j6a3-BH2Hj4xFWJJ18NhAIKbEOBx1VofGirNuJpKNvoq4BvobHJzLrGriL2AS-g8LapvcML23gITTxDJ6VdRhju-wA9302exg_JbH4_Hd_MEseEEgnjuQZRQpbTzBYk0zLVRU6cBGlLApoypSy1JVfM5U5JkaU6B60EYVZmjPIBut7prtt8BYXrvGu7NOvar2z9bSrrzf9J8G_mtdqYTHPNFOkELvcCdfXRQmzMykcHy6UN0N1sWCpkFxdLt1C2g7q6irGG8mBDidk-w2yzNtusDVOGm-4ZHeni74IHym_0_AfKFoTu</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Imburgia, Taylor A</creator><creator>Kussin, Michelle L</creator><general>Pediatric Pharmacy Advocacy Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients</title><author>Imburgia, Taylor A ; Kussin, Michelle L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2474-23b9e4fe8b18ad089569db0c5e5af0e91277a1af372cbc754869be97402a58213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Education</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imburgia, Taylor A</creatorcontrib><creatorcontrib>Kussin, Michelle L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of pediatric pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imburgia, Taylor A</au><au>Kussin, Michelle L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients</atitle><jtitle>The journal of pediatric pharmacology and therapeutics</jtitle><addtitle>J Pediatr Pharmacol Ther</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>27</volume><issue>3</issue><spage>214</spage><epage>227</epage><pages>214-227</pages><issn>1551-6776</issn><eissn>2331-348X</eissn><abstract>Intravenous beta-lactam antibiotics are the most prescribed antibiotic class in US hospitalized patients of all ages; therefore, optimizing their dosing is crucial. Bactericidal killing is best predicted by the time in which beta-lactam drug concentrations are maintained above the organism's minimum inhibitory concentration (MIC), rather than achievement of a high peak concentration. As such, administration of beta-lactam antibiotics via extended or continuous infusions over a minimum of 3 hours, rather than standard infusions over approximately 30 minutes, has been associated with improved achievement of pharmacodynamic targets and improved clinical outcomes in adult medical literature. This review summarizes the pediatric medical literature. Applicable studies include pharmacodynamic models, case series, retrospective analyses, and prospective studies on the use of extended infusion and continuous infusion penicillins, cephalosporins, carbapenems, and monobactams in neonates, infants, children, and adolescents. Specialized patient populations with unique pharmacokinetics and high-risk infections (neonates, critically ill, febrile neutropenia, cystic fibrosis) are also reviewed. While more studies are needed to confirm prospective clinical outcomes, the current body of evidence suggests extended and continuous infusions of beta-lactam antibiotics are well tolerated in children and improve achievement of pharmacokineticpharmacodynamic targets with similar or superior clinical outcomes, particularly in infections associated with high MICs.</abstract><cop>United States</cop><pub>Pediatric Pharmacy Advocacy Group</pub><pmid>35350159</pmid><doi>10.5863/1551-6776-27.3.214</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1551-6776
ispartof The journal of pediatric pharmacology and therapeutics, 2022-01, Vol.27 (3), p.214-227
issn 1551-6776
2331-348X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8939270
source PubMed Central
subjects Education
title A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A28%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Review%20of%20Extended%20and%20Continuous%20Infusion%20Beta-Lactams%20in%20Pediatric%20Patients&rft.jtitle=The%20journal%20of%20pediatric%20pharmacology%20and%20therapeutics&rft.au=Imburgia,%20Taylor%20A&rft.date=2022-01-01&rft.volume=27&rft.issue=3&rft.spage=214&rft.epage=227&rft.pages=214-227&rft.issn=1551-6776&rft.eissn=2331-348X&rft_id=info:doi/10.5863/1551-6776-27.3.214&rft_dat=%3Cproquest_pubme%3E2645470260%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2474-23b9e4fe8b18ad089569db0c5e5af0e91277a1af372cbc754869be97402a58213%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2645470260&rft_id=info:pmid/35350159&rfr_iscdi=true